← brief for 2026-09-18 · Slowing decline

Somatostatin analogues for ADPKD: ending the confusing story of mGFR and eGFR

Paper No results yet Peer reviewed

Key takeaways

This commentary reviews a recent trial of a drug called lanreotide for polycystic kidney disease. The drug did not slow the decline in measured kidney function. However, it did show a slight effect on estimated kidney function. The authors discuss why these two measures can give different results. This piece is an opinion on the trial data, not a new study.

Source

Paper · Kidney International · 2026-10-01
https://www.kidney-international.org/article/S0085-2538(26)00618-6/fulltext?rss=yes